A Study to Examine Anktiva for the Treatment of Long COVID
Phase 2
40
about 11 months
18–70
1 site in CA
What this study is about
This trial is testing if Anktiva can help people with long-term symptoms after a COVID-19 infection. The treatment will last 330 days and involve taking Anktiva medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Anktiva
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg)., Clinically important changes in vital signs such as heart rate in beats per minute., Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration., Incidence of serious adverse events (SAEs) through 30 days post final study drug administration., Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.
Infectious